Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13805030 | 0.90 | ALDH1A1 (0.63) | KDM4EALDH1A1SMN1; SMN2MAPK1APAF1 | |
| SCHEMBL13805027 | 0.88 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2APAF1UBE2N | |
| SCHEMBL13805032 | 0.88 | APAF1 (0.63) | KDM4EALDH1A1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL13805028 | 0.85 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPK1APAF1UBE2N | |
| SCHEMBL5772884 | 0.85 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL13805031 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2MAPK1APAF1 | |
| SCHEMBL13805040 | 0.84 | ALDH1A1 (0.49) | KDM4EALDH1A1SMN1; SMN2MAPK1APAF1 | |
| SCHEMBL5745578 | 0.82 | KMT2A (0.57) | KDM4EALDH1A1HTT | |
| SCHEMBL5798495 | 0.81 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL3929146 | 0.81 | ALDH1A1 (0.59) | KDM4EALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | KDM4E 3692/4885ALDH1A1 883/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.